The evolution of therapeutic modalities drives the adoption of single-use technologies.

Review of SUT Adoption in Biopharma Manufacturing

Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.

Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

 Automating the Future of Fill/Finish

Topic

Articles

Poor API quality may often lead to delays in production and a shortage of supply.

Poor API Quality Threatens a Healthy Supply

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Videos

The PharmTech Group interviewed Edwin Stone, CEO of Cellular Origins, about how geopolitical instability in Europe, and beyond, has impacted the bio/pharmaceutical supply chain.

Industry Outlook 2025: European Political Impacts on the Supply Chain

, is senior manager, Manufacturing Science and Technology (MSAT), at AGC Biologics.

This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.

Understanding the Variability in Bioburden Test Results in Biomanufacturing

Amit Chivate, senior market manager, Greater Asia and China, Roquette, provides his perspective on FDA’s recommendations regarding nitrosamines. 

Strategies for Mitigating Nitrosamine Risk

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.

Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing

BioPharm International® spoke with Lun Xin, associate director at WuXi Biologics, about high-concentration biologics and some of the biggest challenges associated with their formulation.

AAPS National Biotechnology Conference 2025: High-Concentration Biologics

The PharmTech Group interviewed Edwin Stone, CEO of Cellular Origins, about how technological advances will impact the biopharma industry in the future.


Industry Outlook 2025: The Future of Technology in the Biopharma Industry

BioPharm International® sat down with Noah Kopcho, field application scientist at Gyros Protein Technologies, to talk about the challenges in the production of AAV vectors.

AAPS National Biotechnology Conference 2025: AAV Vector Production

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Incorporating sustainable practices into process designs as early as possible ensures optimal performance.

Sustainability by Design in the Context of Bioprocess Development

Feliza Mirasol is the science editor for 

The shift toward personalized medicines poses new challenges in cleanroom protocols.